The future of antidepressants

Biomedicine and Pharmacotherapy

Volumn 50, Issue 1, 1996, Pages 7-12

  Bourin, M ^a   Baker, G B ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antidepressants; G proteins; Receptor

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR; DOPAMINE; NORADRENALIN; PROTEIN G; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; COMPULSION; DEPRESSION; DRUG MECHANISM; DRUG THERAPY; DRUG USE; HUMAN; OBSESSION; PANIC; PHOBIA; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER;

EID: 0030045888     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/0753-3322(96)85091-8     Document Type: Article

References (53)

1. Avissar S, Schreiber G, Danon A, Belmaker RH. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988;331:440
2. Bialik RJ, Ravindran AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci 1995;20:265
3. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-bind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084
4. Birnhaumer L, Avramowitz J, Brown AM. Receptor-effector coupling by G-proteins. Biochem Biophys Acta 1990; 1031:163
5. Blatt C, Eversole-Cire P, Cohn VH. Chromosomal localization of genes encoding guanine nucleotide-binding protein subunits in mouse and humans. Proc Natl Acad Sci USA 1988;85:7641
6. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15:220
7. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacol 1988;95:298
8. Bourin M, Gest D, Baudot S. Sevrage d'une dépendance à l'amineptine par la clonidine? Encephale 1990; XVI:26I
9. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 1993; 16:387
10. Brunello N, Perez J, Tinelli D, Rovescali AC, Racagni G. Biochemical and molecular changes in rat cerebral cortex after chronic antidepressant treatment: in vitro and in vivo studies. Pharmacol Toxicol 1990;66(suppl III): 112
11. Cassano GB, Marazziti D. Is depression a disorder of a receptor superfamily? A critical review of the receptor theory of depression and the appraisal of a new heuristic model. Eur Psychiatry 1992;7:259
12. Deakin JFW, Guimaraes FS, Wang M, Hensman R. Experimental tests of the 5-HT receptor imbalance theory of affective disturbance. In: Sandler M, Coppen A, Harnett S, eds. 5-hydroxytryptamine in Psychiatry - a spectrum of ideas. Oxford: Oxford University Press, 1991
13. Duman RS, Terwiliger RZ, Nestler EJ. Chronic antidepressant regulation of Gsa and cyclic AMP-dependent protein kinase [abstract]. Pharmacologist 1989;31:182
14. 2 mediated behavior in the rat following noradrenergic or serotoninergic denervation. J Neural Transm 1991;84:19
15. Ellingrod VL, Perry Pj. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994;51:3033
16. Ganry H, Bourin M. Iprindole: un lien fonctionnel entre les systèmes noradrénergique et sérotoninergique. Encephale 1994;XX:7
17. Gest D, Bourin M, Besançon G. Un cas de dépendance à l'amineptine accompagné d'un délire paranoïde de type amphétaminique. L'Information Psychiat 1993;69:277
18. Goodnough DB, Baker GB. 5-hydroxytryptamine 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J Neurochem 1994;62:2262
19. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980;10:189
20. Hindmarch I. Relevant psychometric tests for antidepressants and anxiolytics. Int Clin Psychopharmacol 1994, 9 suppl 1:27
21. Hindmarch I, Kerr J. Behavioural toxicity of antidepressanl with particular reference to moclobemide. Psychopharmacology 1992;106:S49
22. Henry JA. A fatal toxicity index for antidepressant poisoning. Acta Psychiat Scand 1989;80:37
23. Hrdina PD. Is there action beyond receptors? J Psychiat Neurosci 1993;18:57
24. 2 receptors in rat brain: an autoradiographic study. Synapse 1993;14:324
25. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993; 13:278
26. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9:19
27. Kasper S, Höflich G, Scholl HP, Möller HJ. Safety and antidepressant efficacy of selective serotonin reuptake inhibitors. Human Psychopharmacol 1994;9:1
28. Klein DF. Delireaction of two drug responsive anxiety syndromes. Psycho-pharmacol 1964;5:397
29. Klein DF. Anxiety reconceptualized. In: Klein DF, Rabkin J, eds. Anxiety: New Research and Changing Concepts. New York: Raven Press, 1981;235
30. Lesch KP, Aulakh CS, Tolliver TJ, Hill JL, Murphy DL. Regulation of G proteins by chronic antidepressant drugs in rat brain: tricyclics but not clorgyline increase Goa subunits. Eur J Pharmacol Mol Sect 1991;207:361
31. Lesch KP, Hough CJ, Aulakh CS et al. Fluoxetine modulates G-protein αs, αq and a 12 subunit messenger RNA expression in rat brain. Eur J Pharmacol Molec Pharm 1992;227:233
32. Levine J. Barak Y, Gonzalves M et al. Double blind, controlled trial of inositol treatment of depression. Am J Psychiat 1995;152:792
33. Liehowitz MR. Reversible MAO inhibitors in social phobia, bulimia and other disorders. Clin Neuropharmacol 1992;15(suppl 1):434A
34. Manji HK. G proteins: implications for psychiatry. Am J Psychiat 1992;149:746
35. Mann CD, Vu TB, Hrdina PD. Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Br J Pharmacol 1995; 115:595
36. Maus M, Homburger V, Bockaerdt J, Glowinski J, Premont J. Pretreatment of mouse striatal neurons in primary culture of 17 β-estradiol enhances the pertussis toxin-catalyzed ADP-ribosylation of G a protein subunits. J Neurochem 1990;55:1244
37. Moor M, Honegger UE, Weissman UN. Organospecific qualitative changes in the phospholipid composition of rats after chronic administration of the antidepressant drug, desipramine. Biochem Pharmacol 1987;37:2035
38. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antide-pressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 1989;53:1644
39. Nestler EJ, Duman RS. Intracellular messenger pathways as mediators of neural plasticity. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995;695
40. 1A receptor-media-ted effects of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiat 1993;17:1
41. Ozawa H. Rasenick MM. Coupling of the stimulatory GTP-binding protein Gs to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment. Mol Pharmacol 1989;36:803
42. Perez J, Tinelli, Brunello N, Racagni G. c-AMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol Mol Pharmacol 1989;172:305
43. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. Arch Gen Psychiat 1993;50:884
44. Saito N, Guitar X, Hayward M, Tallman JF, Duman RS, Nestler E. Corticosterone differentially regulates the expression of Gsa and Gia messenger RNA and protein in rat cerebral cortex. Proc Natl Acad Sci USA 1989;86:3906
45. Schreiber G, Avissar S, Danon A, Belmaker RH. Hyper-functional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiat 1991;29:273
46. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiat 1992;161:562
47. Spiegel AM. Heterotrimetric GTP-binding proteins: an expanding family of signal tranducers. Med Res Rev 1992;12:55
48. 1A receptors and pharmacotherapy. Psychopharmacol Bull 1994;30:39
49. Sulser F. The aminergic "link hypothesis" of affective disorders: a molecular view of therapy-resistant depression. In: Proc. 3rd Ann. Bristol-Myers Squibb Symp on Neurosci Res, Neurobiology of Affective Disorders. New York: Raven Press, 1993;7
50. Todd KG, McManus DJ, Baker GB. Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine 2A receptors without affecting benzodiazepine binding sites in rat brain. Cell Mol Neurobiol 1995;15:361
51. Wachtel H. Dysbalances of neuronal second messenger function on the aetiology of affective disorders: a pathophysiological concept hypothesising defects beyond first messenger receptors. J Neural Transm 1989;75:21
52. Young LT, Li PP, Kish SJ, Siu KP, Kamble A, Hornykiewicz O, Warsh JJ. Cerebral cortex Gsa protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 1993; 61:890
53. Zohar J, Insel T. Drug treatment of obsessive-compulsive disorder. J Affect Dis 1987;13:193